High-throughput liquid chromatography-tandem mass spectrometry assay for plasma theophylline and its metabolites

Clinical Chemistry

Volumn 50, Issue 11, 2004, Pages 2176-2179

  Song, Junghan ^a,b   Park, Kyoung Un ^a,b   Park, Hyung Doo ^a   Yoon, Yeomin ^c   Kim, Jin Q ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Jeju National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,7 DIMETHYLURIC ACID; CAFFEINE; CYTOCHROME P450 1A2; DRUG METABOLITE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

ARTICLE; ASSAY; CALIBRATION; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; TANDEM MASS SPECTROMETRY;

BRONCHODILATOR AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PLASMA; THEOPHYLLINE; URIC ACID; XANTHINES;

EID: 7044274526     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.035337     Document Type: Article

References (19)

1. Bertino JS Jr. Theophylline. In: Schumacher GE, ed. Therapeutic drug monitoring, 1st ed. Stamford, CT: Appleton & Lange, 1995:553-86.
2. Ogilvie RI. Clinical pharmacokinetics of theophylline. Clin Pharmacokinet 1978;3:267-93.
3. Grygiel JJ, Wing LM, Farkas J, Birkett DJ. Effects of allopurinol on theophylline metabolism and clearance. Clin Pharmacol Ther 1979;26:660-7.
4. Kizu J, Watanabe S, Yasuno N, Arakawa Y, Uzu S, Kanda S, et al. Development and clinical application of high performance liquid chromatography for the simultaneous determination of plasma levels of theophylline and its metabolites without interference from caffeine. Biomed Chromatogr 1999;13:15-23.
5. Kanazawa H, Atsumi R, Matsushima Y, Kizu J. Determination of theophylline and its metabolites in biological samples by liquid chromatography-mass spectrometry. J Chromatogr A 2000;870:87-96.
6. Schneider H, Ma L, Glatt H. Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003;789:227-37.
7. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh OH, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:165-71.
8. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996;41:605-8.
9. Tateishi T, Asoh M, Yamaguchi A, Yoda T, Okano YJ, Koitabashi Y, et al. Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients. Pediatr Res 1999;45:66-70.
10. Self TH, Chafin CC, Soberman JE. Effect of disease states on theophylline serum concentrations: are we still vigilant? Am J Med Sci 2000;319:177-82.
11. Mayo PR. Effect of passive smoking on theophylline clearance in children. Ther Drug Monit 2001;23:503-5.
12. Ohnishi A, Kato M, Kojima J, Ushiama H, Yoneko M, Kawai H. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging 2003;20:71-84.
13. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001;11:429-35.
14. Obase Y, Shimoda T, Kawano T, Saeki S, Tomari SY, Mitsuta-Izaki K, et al. Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 2003;73:468-74.
15. Kalow WK, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-14.
16. Rasmussen BB, Brosen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br J Clin Pharmacol 1997;43:253-8.
17. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 2000;22:409-17.
18. Doude van Troostwijk U, Koopmans RP, Guchelaar HJ. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio. Fundam Clin Pharmacol 2003;17:355-62.
19. Terziivanov D, Bozhinova K, Dimitrova V, Atanasova I. Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult Caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. Clin Pharmacokinet 2003;42:1393-409.